SYNBIO POLICY METER

BENEFITS AND COSTS

​

​

What benefits are most relevant?

​

1. Strengthen basic biological research that is more relevant to human subjects than to animal models (μ=7,36; SD=1,37)

2. Biological solutions to the problem of shortage of human organs and tissues” (μ=7,04; SD=1,14)

​

 

Which stakeholders will mostly benefit?

​

1. Private biotechnology firms (μ=7,93; SD=1,15)

2. Patient’s organizations (μ=6,89; SD=1,31)

​

​

What costs are most relevant?

​

1. Difficulty to predict the long-term biological behaviour of synthetic biomaterials implanted in the human body (μ=6,89; SD=1,31)

2. Rise of new ethical issues concerning the production of artificial cells, tissues and organs (μ=6,64; SD=1,59)

​

​

Which stakeholders will have to bear the highest costs ?

​

1. National public health agencies (μ=6,32; SD=1,72)

2. Private biotechnology firms” (μ=6,04; SD=1,82)

​

​

Which stakeholders can have a relevant role in the allocation of costs and benefits ?

 

1. Policy Makers

2. Research Fundings

​

Which procedure should be used to asses the costs and benefits of the application?

 

1. Risk Assessment Procedures

​

​

​

GOVERNANCE AND REGULATORY TOOLS

​

Which governance framework should be used to regulate R&D activities ?

​

1. International guidelines” (μ=7,54; SD=1,10)

​

​

Which procedures should be used to foster compliance with regulatory measures ?

​

1. Legally binding procedures

2. Regularly monitored and evaluated through audit procedures

​

​

Which approaches are most useful in encouraging companies and research organization to comply with regulatory and governance?

​

1. Reputational Incentives (ethical labels, brands, and rankings) (μ=7,00; SD=1,41)

2. Requirement to integrate the adherence to the regulatory measures into research funding through evaluation criteria (μ=6,61; SD=1,34)

​

​

​

< Back to the list